Inflimab, In Combination with Methotrexate, is Indicated for Inhibition of Progression of Structural Damage in RA Patients
Infliximab (Remicade®), in combination with methotrexate, is now indicated for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate. Approval from the Food and Drug Administration (FDA) for the expanded indication came as a result of radiographic and clinical results from a phase III randomized, double-blind, multi-center trial of 420 adults. (more details on study)